BIOMAT Database Logo BIOMAT Database Logo

Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein. 1987

T J Matthews, and A J Langlois, and W G Robey, and N T Chang, and R C Gallo, and P J Fischinger, and D P Bolognesi
Department of Surgery, Duke University Medical School, Durham, North Carolina 27710.

By analogy to other retroviruses, the major envelope glycoprotein - gp120 - of HTLV-III/LAV is a probable target for neutralizing antibody. This antigen has been purified from H9 cells chronically infected with the HTLV-IIIB prototype strain. Several goats immunized with the gp120 produced antibodies that neutralized infection of H9 by the homologous virus isolate. These same sera failed to neutralize the divergent HTLV-IIIRF isolate. Individuals infected with HTLV-III/LAV commonly develop antibodies to gp120 which could be isolated using the gp120 antigen coupled to an immunoadsorbent resin. The antibody fraction that bound tightly to such a resin was found to neutralize the IIIB but not the RF isolate in a fashion similar to that of the goat anti-gp120 sera. However, the nonbinding fraction (effluent) from the resin also contained neutralizing activity which was able to block infection by both virus isolates with similar efficacy. Human antibodies to the other virus envelope gene product, the transmembrane gp41, were also affinity-purified utilizing the recombinant peptide 121, but they failed to influence infection by either virus isolate.

UI MeSH Term Description Entries
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D012191 Retroviridae Proteins Proteins from the family Retroviridae. The most frequently encountered member of this family is the Rous sarcoma virus protein. Leukovirus Proteins,Retrovirus Proteins,Proteins, Leukovirus,Proteins, Retroviridae,Proteins, Retrovirus
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015699 HIV Envelope Protein gp120 External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV. Envelope Glycoprotein gp120, HIV,HTLV-III gp120,env Protein gp120, HIV,gp120(HIV),HIV Envelope Glycoprotein gp120,gp120 Envelope Glycoprotein, HIV,HTLV III gp120,gp120, HTLV-III

Related Publications

T J Matthews, and A J Langlois, and W G Robey, and N T Chang, and R C Gallo, and P J Fischinger, and D P Bolognesi
Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein.
January 1986, Nature,
T J Matthews, and A J Langlois, and W G Robey, and N T Chang, and R C Gallo, and P J Fischinger, and D P Bolognesi
Role of HTLV III/LAV envelope protein.
January 1986, Nature,
T J Matthews, and A J Langlois, and W G Robey, and N T Chang, and R C Gallo, and P J Fischinger, and D P Bolognesi
Neutralization of HTLV-III/LAV replication by antiserum to thymosin alpha 1.
May 1986, Science (New York, N.Y.),
T J Matthews, and A J Langlois, and W G Robey, and N T Chang, and R C Gallo, and P J Fischinger, and D P Bolognesi
LAV/HTLV-III and sperm antibodies.
December 1986, Fertility and sterility,
T J Matthews, and A J Langlois, and W G Robey, and N T Chang, and R C Gallo, and P J Fischinger, and D P Bolognesi
Prevalence of HTLV-III/LAV antibodies among Haitians.
June 1985, The New England journal of medicine,
T J Matthews, and A J Langlois, and W G Robey, and N T Chang, and R C Gallo, and P J Fischinger, and D P Bolognesi
HTLV-III/LAV antibodies in contacts of hemophiliacs.
June 1986, JAMA,
T J Matthews, and A J Langlois, and W G Robey, and N T Chang, and R C Gallo, and P J Fischinger, and D P Bolognesi
LAV/HTLV-III and HTLV-I antibodies in hemodialysis patients.
January 1986, Nephron,
T J Matthews, and A J Langlois, and W G Robey, and N T Chang, and R C Gallo, and P J Fischinger, and D P Bolognesi
The prevalence of HTLV-III/LAV antibodies in heterosexuals.
April 1986, JAMA,
T J Matthews, and A J Langlois, and W G Robey, and N T Chang, and R C Gallo, and P J Fischinger, and D P Bolognesi
Lack of antibodies to HTLV-III/LAV in Danish dentists.
January 1986, JAMA,
T J Matthews, and A J Langlois, and W G Robey, and N T Chang, and R C Gallo, and P J Fischinger, and D P Bolognesi
[Anti-HTLV-III/LAV antibodies in hematology reactives].
January 1986, Sangre,
Copied contents to your clipboard!